Fig. 4: Functional antibody responses elicited in vaccinated and placebo recipient SHIV-infected, ART-treated rhesus monkeys. | npj Vaccines

Fig. 4: Functional antibody responses elicited in vaccinated and placebo recipient SHIV-infected, ART-treated rhesus monkeys.

From: Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1

Fig. 4: Functional antibody responses elicited in vaccinated and placebo recipient SHIV-infected, ART-treated rhesus monkeys.The alternative text for this image may have been generated using AI.

Plasma neutralizing activity against tier 1 viruses, MW965 (a) and CH505 w4.3 (b) and the autologous CH505 (c) virus. Medians are indicated as horizontal lines, vertical dotted line indicates ART stop. Levels of infected cell binding expressed as Mean Fluorescent Intensity to a panel of HIV-1 1086.C or CH505.TF IMC-infected cells over time for each animal are shown (d, e). Maximum granzyme B activity (f, g) and the plasma dilution endpoint ADCC antibody titers (h, i) against 1086.C and CH505 gp120-coated target cells over time for each animal are shown. Statistical analyses were performed using Wilcoxon rank-sum tests with exact p-values to compare plasma IgG neutralization (a–c) and ADCC antibody titers (h, i) between vaccinated and placebo RMs, followed by FDR adjustments for multiple comparisons. *unadjusted p < 0.05, **unadjusted p < 0.01. FDR adjusted p-values are reported in the dot plots. See Supplementary Table 3 for both unadjusted p and FDR_p for all comparisons.

Back to article page